|Day Low/High||375.10 / 418.31|
|52 Wk Low/High||28.00 / 131.00|
Plus, China's central bank plans to cut its Reserve Ratio Requirement and Wells Fargo looks to exit a business line.
Contrary to popular belief, this economic recovery that we seem to be enjoying has hit a pressure point.
There's a split growing at the FOMC as to just how transitory the current burst of consumer level inflation actually is.
CVAC is now working on a 'next generation' COVID-19 vaccine candidate with GlaxoSmithKline.
I prefer the bear put spread over the covered equity play due to the decreased risk to principal, despite the capped potential for profit.
How long have we cried out in the wilderness with no one listening? Finally, perhaps, a champion has risen from the depths.
Last year's top-performing stock market worldwide has been a disappointment since setting an all-time high in February. Could it have just turned?
We've been caught with our pants down, largely because we had no faith in the smartest people in the country.
The market seems to rejoice from the latest mask utterance out of the CDC, but the action at the Nasdaq should give traders pause.
ARCT's IP is incredibly valuable, and may in fact be invaluable.
The market came within whiskers of a technical breakdown on Thursday, yet few people seem to know or care.
The fund is at a key spot technically, and there is real fear that if this spot cracks, what looks like a stretch of rough rapids could become a waterfall.
PFE reported Q1 earnings Tuesday and handily beat expectations.
UPS and FDX are both in serious rally mode, yet in very different places in terms of technical development.
Markets in Tokyo, Mumbai and most of Southeast Asia are down this month, Asia's early progress in combatting COVID-19 proving hard to sustain.
Don't forget, this is a very large company with a lot more than the vaccine going on.
My COVID vaccine eligibility actually began about a week before my symptoms began.
The main story unfolded along with the passing hours on Monday, and continues. The ending of this tale perhaps remains far from untold.
Lies, damn lies, and statistics in the vaccine age, as Hong Kong and Macau stop administering the Pfizer/BioNTech drug.
Here's my view on this space and where the money is to be made.
Let's look back at how the market reacted to COVID-19 one year ago, and the lessons we can learn.
COVID numbers stopped improving a while ago, even with ever-improving rates of vaccination. Just what is going on here?
The market's catalyst had everything to do with the virus... optimism that humankind might stuff that scourge back into Pandora's box.
The funny thing about flat lines is that the move at the end is usually explosive, but could go either way.
While there are certainly some things to like about AZN, I don't think this vaccine, nor the UK emergency authorization, make it investable.
Are traders working this holiday shortened week? You bet they are.